Insys Therapeutics Stock Price, News & Analysis (NASDAQ:INSY)

$7.93 +0.34 (+4.48 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$7.93
Today's Range$7.60 - $8.20
52-Week Range$4.10 - $15.02
Volume567,349 shs
Average Volume1.45 million shs
Market Capitalization$581.40 million
P/E Ratio-3.11
Dividend YieldN/A
Beta0.78

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Receive INSY News and Ratings via Email

Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:INSY
CUSIPN/A
Phone+1-602-9102617

Debt

Debt-to-Equity RatioN/A
Current Ratio0.86%
Quick Ratio0.77%

Price-To-Earnings

Trailing P/E Ratio-3.10980392156863
Forward P/E Ratio-12.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$242.27 million
Price / Sales2.40
Cash Flow$0.27 per share
Price / Cash29.47
Book Value$3.76 per share
Price / Book2.11

Profitability

Trailing EPS($2.55)
Net Income$7.59 million
Net Margins-112.56%
Return on Equity-11.76%
Return on Assets-7.90%

Miscellaneous

Employees423
Outstanding Shares73,320,000

Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Shares of Insys Therapeutics split on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were payable to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics Inc (NASDAQ:INSY) announced its earnings results on Monday, April, 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.00 by $0.03. The specialty pharmaceutical company had revenue of $54.86 million for the quarter, compared to the consensus estimate of $52.08 million. Insys Therapeutics had a negative return on equity of 11.76% and a negative net margin of 112.56%. Insys Therapeutics's quarterly revenue was down 41.6% on a year-over-year basis. During the same period last year, the firm posted $0.42 EPS. View Insys Therapeutics' Earnings History.

When will Insys Therapeutics make its next earnings announcement?

Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April, 2nd 2018. View Earnings Estimates for Insys Therapeutics.

Where is Insys Therapeutics' stock going? Where will Insys Therapeutics' stock price be in 2018?

4 analysts have issued 12-month target prices for Insys Therapeutics' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Insys Therapeutics' share price to reach $9.67 in the next twelve months. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:

  • Steven J. Meyer, Independent Chairman of the Board (Age 60)
  • Saeed Motahari, President, Chief Executive Officer, Director (Age 51)
  • Andrew G. Long, Chief Financial Officer
  • Venkat R. Goskonda, Senior Vice President - Research & Development
  • Steve Sherman, Senior Vice President - Regulatory Affairs
  • Franc Del Fosse, General Counsel, Corporate Secretary (Age 45)
  • Rohit Vishnoi, Director
  • Pierre Lapalme, Independent Director (Age 76)
  • Vaseem Mahboob, Independent Director (Age 48)
  • Brian Tambi, Independent Director (Age 71)

Who owns Insys Therapeutics stock?

Insys Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.49%), Geode Capital Management LLC (0.34%), QS Investors LLC (0.23%), Goldman Sachs Group Inc. (0.16%), Bank of New York Mellon Corp (0.15%) and Schwab Charles Investment Management Inc. (0.12%). Company insiders that own Insys Therapeutics stock include Daniel Brennan, John N Kapoor Trust Dated Sept, Patrick Fourteau, Rohit Vishnoi, Saeed Motahari, Steven J Meyer and Theodore H Stanley. View Institutional Ownership Trends for Insys Therapeutics.

Who sold Insys Therapeutics stock? Who is selling Insys Therapeutics stock?

Insys Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Goldman Sachs Group Inc., Schwab Charles Investment Management Inc., Geode Capital Management LLC, QS Investors LLC and Rhumbline Advisers. View Insider Buying and Selling for Insys Therapeutics.

Who bought Insys Therapeutics stock? Who is buying Insys Therapeutics stock?

Insys Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Wells Fargo & Company MN, Raymond James & Associates, Stone Ridge Asset Management LLC, Virtu Financial LLC and Alliancebernstein L.P.. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy Insys Therapeutics stock?

Shares of Insys Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of Insys Therapeutics stock can currently be purchased for approximately $7.93.

How big of a company is Insys Therapeutics?

Insys Therapeutics has a market capitalization of $581.40 million and generates $242.27 million in revenue each year. The specialty pharmaceutical company earns $7.59 million in net income (profit) each year or ($2.55) on an earnings per share basis. Insys Therapeutics employs 423 workers across the globe.

How can I contact Insys Therapeutics?

Insys Therapeutics' mailing address is 10220 S 51st St Ste 2, PHOENIX, AZ 85044-5231, United States. The specialty pharmaceutical company can be reached via phone at +1-602-9102617.


MarketBeat Community Rating for Insys Therapeutics (INSY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  502
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Insys Therapeutics (NASDAQ:INSY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.67$9.67$9.67$12.67
Price Target Upside: 87.34% upside87.34% upside87.34% upside26.41% upside

Insys Therapeutics (NASDAQ:INSY) Consensus Price Target History

Price Target History for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ:INSY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2017OppenheimerReiterated RatingHoldN/AView Rating Details
11/3/2017Jefferies GroupLower Price TargetBuy$14.00 -> $11.00N/AView Rating Details
10/27/2017Royal Bank of CanadaSet Price TargetBuy$8.00N/AView Rating Details
7/26/2017Piper Jaffray CompaniesSet Price TargetHold$10.00MediumView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Insys Therapeutics (NASDAQ:INSY) Earnings History and Estimates Chart

Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ INSY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/2/2018N/AView Earnings Details
11/2/2017Q3 2017($0.23)($0.25)$34.98 million$30.67 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.09)$0.03$36.90 million$42.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)($0.09)$37.78 million$35.92 millionViewListenView Earnings Details
4/3/2017Q4 2016$0.00$0.03$52.08 million$54.86 millionViewN/AView Earnings Details
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.16$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.40$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.48$52.77 million$55.70 millionViewN/AView Earnings Details
5/13/2014Q1 2014$0.14$0.18$46.00 million$41.64 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
8/26/2010Q2 2010($0.59)ViewN/AView Earnings Details
6/11/2010Q1 2010($1.02)ViewN/AView Earnings Details
3/18/2010Q4 2009($0.33)ViewN/AView Earnings Details
10/26/2009Q3 2009($1.26)ViewN/AView Earnings Details
7/27/2009Q2 2009($1.42)ViewN/AView Earnings Details
4/28/2009Q1 2009($1.61)ViewN/AView Earnings Details
3/4/2009Q4 2008($1.59)ViewN/AView Earnings Details
11/12/2008Q3 2008($1.71)ViewN/AView Earnings Details
8/14/2008Q2 2008($1.48)ViewN/AView Earnings Details
5/12/2008Q1 2008($1.08)ViewN/AView Earnings Details
3/27/2008Q4 2007($0.75)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Insys Therapeutics (NASDAQ:INSY) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.63 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS

Dividends

Dividend History for Insys Therapeutics (NASDAQ:INSY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insys Therapeutics (NASDAQ INSY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 67.90%
Institutional Ownership Percentage: 24.83%
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ INSY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2017John N Kapoor Trust Dated SeptMajor ShareholderBuy17,500$8.93$156,275.0031,982View SEC Filing  
8/10/2017Saeed MotahariCEOBuy5,500$8.92$49,060.0015,400View SEC Filing  
6/14/2017Saeed MotahariCEOBuy5,400$11.10$59,940.009,900View SEC Filing  
6/1/2017Rohit VishnoiDirectorBuy4,000$14.14$56,560.004,000View SEC Filing  
5/18/2017Steven J MeyerDirectorBuy8,000$12.21$97,680.0052,083View SEC Filing  
5/16/2017Saeed MotahariCEOBuy4,500$11.98$53,910.004,500View SEC Filing  
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.0044,083View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.0017,000View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.0031,982View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.0049,682View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.961View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.0018,000View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.0031,982View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.0064,682View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.0031,982View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.0031,982View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.0079,682View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.002,000View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.006,100View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00105,000View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.243,125View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.565,375View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.003,125View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.003,125View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.003,125View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.0078,557View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.0065,000View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Insys Therapeutics (NASDAQ INSY) News Headlines

Source:
DateHeadline
INSYS Therapeutics to Present at RBC Healthcare Conference - GlobeNewswire (press release)INSYS Therapeutics to Present at RBC Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 20 at 3:16 PM
INSYS Therapeutics to Present at RBC Healthcare Conference ... - GlobeNewswire (press release)INSYS Therapeutics to Present at RBC Healthcare Conference ... - GlobeNewswire (press release)
www.globenewswire.com - February 20 at 3:16 PM
Wonder Women Of Weed: Jodie Emery, The Entrepreneurial Rebel With A CauseWonder Women Of Weed: Jodie Emery, The Entrepreneurial Rebel With A Cause
finance.yahoo.com - February 20 at 3:16 PM
Insys Therapeutics Inc (INSY) Receives Average Rating of "Hold" from BrokeragesInsys Therapeutics Inc (INSY) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 20 at 1:36 AM
Imprimis Pharmaceuticals (IMMY) vs. Insys Therapeutics (INSY) Head to Head ReviewImprimis Pharmaceuticals (IMMY) vs. Insys Therapeutics (INSY) Head to Head Review
www.americanbankingnews.com - February 15 at 7:20 PM
Nevada doctor indicted after patient overdoses on Insys-produced opioid - ReutersNevada doctor indicted after patient overdoses on Insys-produced opioid - Reuters
www.reuters.com - February 15 at 5:19 AM
Opioid Litigants Get Boost From Senate ReportOpioid Litigants Get Boost From Senate Report
finance.yahoo.com - February 13 at 3:15 PM
Opioid makers paid millions to advocacy groups: US Senate report - ReutersOpioid makers paid millions to advocacy groups: US Senate report - Reuters
www.reuters.com - February 13 at 5:16 AM
Opioid makers paid millions to advocacy groups -U.S. Senate reportOpioid makers paid millions to advocacy groups -U.S. Senate report
finance.yahoo.com - February 13 at 5:16 AM
Financial Contrast: Progenics Pharmaceuticals (PGNX) and Insys Therapeutics (INSY)Financial Contrast: Progenics Pharmaceuticals (PGNX) and Insys Therapeutics (INSY)
www.americanbankingnews.com - February 11 at 3:21 PM
Stocks give up early gains, Trump signs budget billStocks give up early gains, Trump signs budget bill
finance.yahoo.com - February 11 at 3:15 PM
Insys Therapeutics (INSY) Releases Statement on Maryland Attorney Generals MotionInsys Therapeutics (INSY) Releases Statement on Maryland Attorney General's Motion
www.streetinsider.com - February 11 at 5:15 AM
INSYS Therapeutics Addresses Maryland Attorney Generals Motion - GlobeNewswire (press release)INSYS Therapeutics Addresses Maryland Attorney General's Motion - GlobeNewswire (press release)
globenewswire.com - February 9 at 3:15 PM
INSYS Therapeutics Addresses Maryland Attorney General’s MotionINSYS Therapeutics Addresses Maryland Attorney General’s Motion
finance.yahoo.com - February 9 at 3:15 PM
Maryland sues Insys to enforce subpoena in opioid probe - Reuters - ReutersMaryland sues Insys to enforce subpoena in opioid probe - Reuters - Reuters
www.reuters.com - February 9 at 5:12 AM
Maryland sues Insys to enforce subpoena in opioid probeMaryland sues Insys to enforce subpoena in opioid probe
finance.yahoo.com - February 9 at 5:12 AM
Insys Vs. New York: Political Theater Trumps Real Legal Issues ... - Seeking AlphaInsys Vs. New York: Political Theater Trumps Real Legal Issues ... - Seeking Alpha
seekingalpha.com - February 7 at 3:15 PM
See which Valley public companies were among U.S. stocks that suffered the most last weekSee which Valley public companies were among U.S. stocks that suffered the most last week
finance.yahoo.com - February 6 at 5:10 AM
 Analysts Anticipate Insys Therapeutics Inc (INSY) to Post -$0.11 Earnings Per Share Analysts Anticipate Insys Therapeutics Inc (INSY) to Post -$0.11 Earnings Per Share
www.americanbankingnews.com - February 5 at 7:40 AM
Insys Therapeutics (INSY) Rating Lowered to Sell at Zacks Investment ResearchInsys Therapeutics (INSY) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 3 at 11:58 AM
New York accuses Insys of deceptively marketing opioid - Reuters - ReutersNew York accuses Insys of deceptively marketing opioid - Reuters - Reuters
www.reuters.com - February 3 at 5:14 AM
Insys Therapeutics (INSY) Releases Statement Addressing New York Attorney Generals Complaint - StreetInsider.comInsys Therapeutics (INSY) Releases Statement Addressing New York Attorney General's Complaint - StreetInsider.com
www.streetinsider.com - February 2 at 3:15 PM
INSYS Therapeutics Addresses New York Attorney Generals Complaint - GlobeNewswire (press release)INSYS Therapeutics Addresses New York Attorney General's Complaint - GlobeNewswire (press release)
globenewswire.com - February 2 at 5:10 AM
New York accuses Insys of deceptively marketing opioid - ReutersNew York accuses Insys of deceptively marketing opioid - Reuters
www.reuters.com - February 1 at 3:12 PM
New York AG goes after Insys; shares down 6% - Seeking AlphaNew York AG goes after Insys; shares down 6% - Seeking Alpha
seekingalpha.com - February 1 at 3:12 PM
INSYS Therapeutics Appoints Vaseem Mahboob to Board of ... - GlobeNewswire (press release)INSYS Therapeutics Appoints Vaseem Mahboob to Board of ... - GlobeNewswire (press release)
globenewswire.com - February 1 at 3:12 PM
INSYS Therapeutics Appoints Vaseem Mahboob to Board of DirectorsINSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors
finance.yahoo.com - February 1 at 3:12 PM
New York accuses Insys of deceptively marketing opioidNew York accuses Insys of deceptively marketing opioid
finance.yahoo.com - February 1 at 3:12 PM
INSYS Therapeutics Adds Two New Executives to Senior Management Team - GlobeNewswire (press release)INSYS Therapeutics Adds Two New Executives to Senior Management Team - GlobeNewswire (press release)
globenewswire.com - January 31 at 5:16 AM
INSYS Therapeutics Adds Two New Executives to Senior Management Team - NasdaqINSYS Therapeutics Adds Two New Executives to Senior Management Team - Nasdaq
www.nasdaq.com - January 30 at 3:11 PM
INSYS Therapeutics Adds Two New Executives to Senior Management TeamINSYS Therapeutics Adds Two New Executives to Senior Management Team
finance.yahoo.com - January 30 at 3:11 PM
Insys Therapeutics Inc (INSY) Given Average Recommendation of "Hold" by BrokeragesInsys Therapeutics Inc (INSY) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 26 at 1:24 AM
Cannabis Industry Group Announces National Standards, Starts With Marijuana Product Packaging And LabelingCannabis Industry Group Announces National Standards, Starts With Marijuana Product Packaging And Labeling
finance.yahoo.com - January 25 at 5:15 AM
What Vermont Can Learn from Washington’s Marijuana TaxWhat Vermont Can Learn from Washington’s Marijuana Tax
finance.yahoo.com - January 23 at 3:17 PM
The Marijuana Ecosystem’s Potential Business OpportunitiesThe Marijuana Ecosystem’s Potential Business Opportunities
finance.yahoo.com - January 23 at 7:54 AM
Is Investment in the Marijuana Space Picking Up?Is Investment in the Marijuana Space Picking Up?
finance.yahoo.com - January 22 at 3:17 PM
Zacks: Brokerages Expect Insys Therapeutics Inc (INSY) Will Post Quarterly Sales of $32.27 MillionZacks: Brokerages Expect Insys Therapeutics Inc (INSY) Will Post Quarterly Sales of $32.27 Million
www.americanbankingnews.com - January 21 at 10:56 AM
5 Big Questions for 1 of the Hottest Marijuana Stocks on the Market - Motley Fool5 Big Questions for 1 of the Hottest Marijuana Stocks on the Market - Motley Fool
www.fool.com - January 15 at 3:32 PM
How Investors Can Access the Marijuana IndustryHow Investors Can Access the Marijuana Industry
finance.yahoo.com - January 15 at 11:14 AM
Ex-Insys employee seeks ban on mentioning opioid crisis at trial - ReutersEx-Insys employee seeks ban on mentioning 'opioid crisis' at trial - Reuters
www.reuters.com - January 13 at 3:30 PM
What’s behind Insys Therapeutics’ Legal Tangles?What’s behind Insys Therapeutics’ Legal Tangles?
finance.yahoo.com - January 12 at 5:28 PM
Insys Therapeutics Inc (INSY) Short Interest UpdateInsys Therapeutics Inc (INSY) Short Interest Update
www.americanbankingnews.com - January 12 at 3:14 AM
Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Tops Q4 EstimatesMid-Morning Market Update: Markets Open Higher; Delta Air Lines Tops Q4 Estimates
www.nasdaq.com - January 11 at 3:34 PM
'New' Fund Soars To Record High: Is Cannabis The New Bitcoin?'New' Fund Soars To Record High: Is Cannabis The New Bitcoin?
finance.yahoo.com - January 10 at 11:37 AM
Ex-Insys employee in federal kickback case may face state chargesEx-Insys employee in federal kickback case may face state charges
www.reuters.com - January 9 at 9:11 AM
Your 2018 Guide to Investing in Marijuana StocksYour 2018 Guide to Investing in Marijuana Stocks
finance.yahoo.com - January 7 at 10:03 AM
Investors Purchase Large Volume of Put Options on Insys Therapeutics (INSY)Investors Purchase Large Volume of Put Options on Insys Therapeutics (INSY)
www.americanbankingnews.com - January 7 at 2:40 AM
Here's Why Marijuana Stocks Got Crushed TodayHere's Why Marijuana Stocks Got Crushed Today
finance.yahoo.com - January 5 at 10:44 AM
Why Buckle, Insys Therapeutics, and United Natural Foods Slumped Today - Motley FoolWhy Buckle, Insys Therapeutics, and United Natural Foods Slumped Today - Motley Fool
www.fool.com - January 4 at 5:40 PM
Why Insys Therapeutics Inc. Crashed Today - Motley FoolWhy Insys Therapeutics Inc. Crashed Today - Motley Fool
www.fool.com - January 4 at 5:40 PM

SEC Filings

Insys Therapeutics (NASDAQ:INSY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Insys Therapeutics (NASDAQ:INSY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Insys Therapeutics (NASDAQ INSY) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.